Astellas to buy US biopharmaceutical firm Propella for $175m
Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Nov 23
Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Nov 23
Novo Nordisk’s new investment will expand its Kalundborg facilities to support the current and future product portfolio within…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Nov 23
The deal is expected to strengthen Alfasigma's pipeline, including the addition of a novel fixed-dose combination that has…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 23
Glenmark's current portfolio consists of 189 products authorized for distribution in the U.S. marketplace and 50 ANDA's pending…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Nov 23
ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader intended to treat acute myeloid leukaemia (AML) and other CD33-expressing malignancies,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Nov 23
The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Nov 23
Under the terms of the expanded partnership, the French drugmaker will extend its licencing rights to Ebvallo in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Nov 23
GSK intends to evaluate JNJ-3989 in a sequential regimen with bepirovirsen, its investigational antisense oligonucleotide designed to identify…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Oct 23
These funds along with other potential funding sources, are anticipated to continue to advance the ATI-1701 program toward…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Oct 23
The Swiss drugmaker will make an upfront of $7.1bn and a near-term milestone payment of $150m, for rights…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates